COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 12 of 14 for:    lestaurtinib

Study of CEP-701 in Treatment of Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00081601
Recruitment Status : Completed
First Posted : April 19, 2004
Last Update Posted : August 24, 2012
Information provided by (Responsible Party):
Teva Pharmaceutical Industries ( Cephalon )

Brief Summary:
The purpose of this study is to determine the proportion of patients with a serological prostate specific antigen (PSA) by day 85.

Condition or disease Intervention/treatment Phase
Prostate Cancer Drug: CEP-701 Phase 2

Detailed Description:
A serological PSA response is defined as a reduction from baseline PSA serum concentration of at least 50%, which is confirmed by a second PSA value 28 or more days later.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 30 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Phase 2 Study of Oral CEP-701 in Patients With Asymptomatic Hormone-Refractory Cancer With Rising Prostate Specific Antigen
Study Start Date : March 2004
Actual Primary Completion Date : May 2005
Actual Study Completion Date : June 2005

Resource links provided by the National Library of Medicine

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • at least 18 yrs of age
  • diagnosis of adenocarcinoma of the prostate
  • no detectable metastatic disease as assessed by bone and CT scans
  • has increasing serum PSA concentrations
  • life expectancy of at least 3 months
  • ECOG of 0 or 1
  • has been withdrawn from antiandrogen therapy for at least 6 weeks prior to entering screening period

Exclusion Criteria:

  • has asymptomatic disease
  • has active GI ulceration or bleeding
  • has been treated with non-hormonal systemic anticancer therapy or has received radiation within 4 weeks of baseline visit
  • bilirubin >2x ULN or ALT or AST >2xULN or serum creatinine >1.5mg/dL
  • hemoglobin <9g/dL or platelets below 100,000/uL or ANC below 1500/uL
  • receiving treatment for HIV with protease inhibitors
  • has had prior malignancy within past 5 yrs with exception of resected basal or squamous cell carcinomas of the skin
  • has used investigational drug with previous one month

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00081601

Layout table for location information
United States, Maryland
Johns Hopkins
Baltimore, Maryland, United States, 21287
Sponsors and Collaborators
Layout table for additonal information
Responsible Party: Cephalon Identifier: NCT00081601    
Other Study ID Numbers: C0701a/203/ON/US
First Posted: April 19, 2004    Key Record Dates
Last Update Posted: August 24, 2012
Last Verified: August 2012
Keywords provided by Teva Pharmaceutical Industries ( Cephalon ):
prostate cancer
prostate specific antigen
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Prostatic Diseases